Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Panos Kefalas

Panos Kefalas

Head of Health Economics & Market Access, Cell & Gene Therapy Catapult

Panos Kefalas is the Head of the Health Economics and Market Access function at the Cell and Gene Therapy Catapult which provides health economics, pricing, reimbursement and market access expertise to accelerate and maximize cell and gene therapy uptake across major healthcare markets.  He brings 18 years’ experience in pharmaceutical pricing, reimbursement and health economics gained both from senior roles with major HEOR and market access consultancy firms (IMS Health plc,  PriceSpective / ICON plc, United BioSource Corporation / Evidera plc) and from managing NICE guidance development. He obtained a PhD in Molecular Medicine from King’s College London, an MBA from Cranfield University and professional training in Health Economics from the University of Oxford and the Centre for Health Economics in York.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd